Eric Austin

Eric Austin has extensive work experience in the field of toxicology and ADME. Eric began their career in 1996 as a Staff Scientist at AMUR Pharmaceuticals, Inc., where they were a project manager for a proprietary drug development project and managed laboratory resources. In 1998, they moved to Covance Laboratories as a Study Director, responsible for directing nonclinical studies in the areas of acute, subchronic, and chronic toxicology. In 2002, they joined ICOS Corporation as a Senior Staff Scientist/Toxicologist, responsible for the design and oversight of contracted drug safety studies. From 2007 to 2010, they were a Senior Toxicology Consultant at Veritox, Inc., providing expertise in toxicology and ADME from early lead optimization through phase 3 and registration. In 2010, they became the Owner of Austin Preclinical Consulting, providing expertise and management of all aspects of preclinical drug development. In 2012, they joined Acucela Inc. as a Senior Manager, Toxicology, providing comprehensive preclinical support for ocular therapies. In 2019, they became the Senior Director, Head of Toxicology at Kintai Therapeutics, responsible for all toxicology programs. In 2020, they were appointed Head of Integrated Pharmacology Research at Gilgamesh Pharmaceutical. Finally, in 2022, they were promoted to Head of Toxicology and ADME at Gilgamesh Pharmaceuticals.

Eric Austin obtained their Bachelor of Science in Microbiology from the University of California, Los Angeles between 1983 and 1987. Eric then went on to earn a Ph.D. in Pharmacology and Toxicology from Washington State University between 1990 and 1996. In 2004, they obtained a DABT certification from the American Board of Toxicology, Inc.